Critical Appraisal of Current Acute LBP Management and the Role of a Multimodal Analgesia: A Narrative Review

Hanna, Magdi; Perrot, Serge; Varrassi, Giustino

doi:10.1007/s40122-023-00479-0

Cited by 3 publications

(2 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In summary, the collection not only expands our understanding of this complex condition but also reinforces the imperative of collaboration, interdisciplinary approaches, and patient-centric care [22]. By leveraging the insights provided by these articles, healthcare professionals, researchers, and policymakers can make meaningful strides in improving outcomes and enhancing the quality of life for individuals living with chronic pain.…”

mentioning

confidence: 83%

Editorial to the Special Issue: “Recent Advances in the Management of Chronic Pain”

Cascella

2023

IJERPH

View full text Add to dashboard Cite

show abstract

mentioning

confidence: 83%

Editorial to the Special Issue: “Recent Advances in the Management of Chronic Pain”

Cascella

2023

IJERPH

View full text Add to dashboard Cite

show abstract

“…It affects between a third and half of the population worldwide [ 2 ]. Complete relief from chronic pain is often unrealistic and integrated pain management using multimodal therapies is currently the advocated strategy [ 3 ]. These therapies may include exercise, physical therapy, massage, cognitive and behavioral therapy, mind–body practices, neuroablative or neuromodulative treatments and drugs [ 4 ].…”

Section: Introductionmentioning

confidence: 99%

Extended Treatment with Micron-Size Oral Palmitoylethanolamide (PEA) in Chronic Pain: A Systematic Review and Meta-Analysis

Schweiger,

Schievano,

Martini

et al. 2024

Nutrients

Self Cite

View full text Add to dashboard Cite

Palmitoylethanolamide (PEA) emerged over the years as a promising approach in the management of chronic pain. Despite the fact that the efficacy of micron-size PEA formulations appears to be time-dependent, the optimal timing has not yet been elucidated. This systematic review and meta-analysis aim to estimate the possible advantage of an extended treatment in the relief of chronic pain. The literature search was conducted consulting scientific databases, to identify clinical trials in which micron-size PEA was administered for at least 60 days, and pain assessed by the Visual Analogue Scale (VAS) or Numeric Rating Scale (NRS). Nine studies matched the required criteria, for a total of 742 patients involved. The meta-analysis showed a statistically and clinically significant pain intensity reduction after 60 days of micron-size PEA supplementation, compared to 30 days (1.36 points, p < 0.01). The secondary analysis revealed a weighted NRS/VAS score decrease of 2.08 points within the first month of treatment. These two obtained scores corresponded to a 35.1% pain intensity reduction within the first month, followed by a further 35.4% during the second month. Overall, these results confirm the clinically relevant and time-depended pain-relieving effect of micron-size PEA and therefore the advantage of an extended treatment, especially in patient with incomplete pain management.

show abstract

Immune Competence and Pain: A Narrative Review

Coaccioli,

Sarzi-Puttini,

Fornasari

et al. 2024

Curr Pain Headache Rep

View full text Add to dashboard Cite

Critical Appraisal of Current Acute LBP Management and the Role of a Multimodal Analgesia: A Narrative Review

Cited by 3 publications

References 100 publications

Editorial to the Special Issue: “Recent Advances in the Management of Chronic Pain”

Editorial to the Special Issue: “Recent Advances in the Management of Chronic Pain”

Extended Treatment with Micron-Size Oral Palmitoylethanolamide (PEA) in Chronic Pain: A Systematic Review and Meta-Analysis

Immune Competence and Pain: A Narrative Review

Contact Info

Product

Resources

About